Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from CellSource Co., Ltd. ( (JP:4880) ) is now available.
CellSource Co., Ltd. reported its consolidated financial results for the six months ended April 30, 2025, under Japanese GAAP. The company achieved net sales of ¥1,820 million and a profit attributable to owners of ¥11 million. The equity-to-asset ratio stood at 85.1%, reflecting a strong financial position. The company has transitioned to consolidated accounting from the fiscal year ending October 31, 2025, which impacts the comparability of year-on-year changes. The financial forecast for the full year ending October 31, 2025, projects net sales of ¥4,501 million and a profit attributable to owners of ¥255 million.
The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry and is listed on the Tokyo Stock Exchange. The company focuses on developing and providing innovative cell-based therapies and regenerative medicine solutions.
Average Trading Volume: 69,300
Technical Sentiment Signal: Sell
Current Market Cap: Yen13.83B
For a thorough assessment of 4880 stock, go to TipRanks’ Stock Analysis page.